Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November
October 24 2017 - 8:05AM
Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage
biopharmaceutical company, today announced that Scott D. Myers,
President and Chief Executive Officer, will participate in two
panel discussions in the month of November.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/02938d7b-513e-467d-b9af-44a422fc2a16
November 7-8, 2017Boston Biotech Conferences NY/NJ CEO, Apella
at Alexandria Center, NY, NYPanel: State of the Markets: Biotech
and PharmaMore information on the conference can be found at
http://bbbiotechconference.com/ceo-meetings.php
November 13-14, 2017YJP CEO Europe Forum in Berlin will feature
a Healthcare Innovation SymposiumPanel: Transitioning from an
R&D Company to a Commercial VentureMore information on YJP and
this meeting can be found at http://access.yjp.org/e/er4ka_4
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative product candidates for
the treatment of cancer. Its lead product candidate, tucatinib, is
an investigational oral, selective small molecule kinase inhibitor
that is highly selective for HER2 and the Company’s lead product in
development for the treatment of HER2 overexpressing cancers.
Cascadian Therapeutics is conducting a randomized, double-blind,
controlled pivotal clinical trial called HER2CLIMB, which is
comparing tucatinib vs. placebo, each in combination with
capecitabine and trastuzumab, in patients with locally advanced or
metastatic HER2+ breast cancer with and without brain metastases,
who have previously been treated with trastuzumab, pertuzumab and
T-DM1. Additional details on HER2CLIMB can be found at
www.HER2CLIMB.com or www.clinicaltrials.gov. For more information,
please visit www.cascadianrx.com.
Investor and Media Contact:Monique
GreerCascadian Therapeutics206-801-2107mgreer@cascadianrx.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2023 to Apr 2024